Research programme: anti-CD4 molecules - Adeona Pharmaceuticals

Drug Profile

Research programme: anti-CD4 molecules - Adeona Pharmaceuticals

Latest Information Update: 06 May 2011

Price : $50

At a glance

  • Originator Thomas Jefferson University
  • Developer Adeona Pharmaceuticals
  • Class Cyclic peptides; Small molecules
  • Mechanism of Action CD4 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Immunological disorders

Most Recent Events

  • 31 Mar 2011 Discontinued for Immunological disorders in USA (PO)
  • 28 Feb 2008 Early research in Immunological disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top